Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 3, 2010, Pages 454-462

  Fabbro, Doriano ^a   Manley, Paul W ^a   Jahnke, Wolfgang ^a   Liebetanz, Janis ^a   Szyttenholm, Alexandra ^a   Fendrich, Gabriele ^a   Strauss, Andre ^a   Zhang, Jianming ^c   Gray, Nathanael S ^c   Adrian, Francisco ^b   Warmuth, Markus ^a   Pelle, Xavier ^a   Grotzfeld, Robert ^a   Berst, Frederic ^a   Marzinzik, Andreas ^a   Cowan Jacob, Sandra W ^a   Furet, Pascal ^a   Mestan, Jürgen ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GNF   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Abl; Abl structure; Imatinib resistance; Kinase inhibitors; Myristate binders

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; AMM 710; AMM 714; AP 24534; BCR ABL PROTEIN; DASATINIB; IMATINIB; MYRISTIC ACID; NILOTINIB; TADIGNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; WILD TYPE; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION, MISSENSE; MYRISTIC ACID; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES;

PYRONIA TITHONUS;

EID: 75349104148     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.12.009     Document Type: Article

References (47)

1. Cohen P. Protein kinases - the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
2. Zhang J., Yang P.L., and Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9 (2009) 28-39
3. Pearson M., Garcia-Echeverria C., and Fabbro D. Protein tyrosine kinases as target for cancer and other indications. In: Fabbro D., and McCormick F. (Eds). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (2006), Humana Press, Totowa NJ 1-31
4. Vieth M., Sutherland J.J., Robertson D.H., and Campbell R.M. Kinomics: characterizing the therapeutically validated kinase space. Drug Discov. Today 10 (2005) 839-846
5. Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S., Markowitz S., Willson J.K.V., Parmigiani G., Kinzler K.W., Vogelstein B., and Vesculescu V.E. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300 (2003) 949-950
6. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teaque H., Butler A., Stevens C., O'Meara E.S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill A.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E., deFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.P., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., and Stratton M.R. Pattern of somatic mutations in human cancer genomes. Nature 446 (2007) 153-158
7. Blencke S., Zech B., Engkvist O., Greff Z., O{double acute}rfi L., Horváth L., Kéri G., Ullrich A., and Daub H. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11 (2004) 691-701
8. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
9. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.A., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonson B., Taylor K., Baccarani M., So C., Letvak L., and Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355 (2006) 2408-2417
10. Fabbro D., Fendrich G., Guez V., Meyer T., Furet P., Mestan J., Griffin J.D., Manley P.W., and Cowan-Jacob S.W. Targeted therapy with imatinib: an exception or a rule?. Handbook of Experimental Pharmacology 167, Inhibitors of Protein Kinases and Protein Phosphates (2005) 361-389
11. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
12. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
13. Weisberg E., Manley P.W., Breitenstein W., Brüggen J., Cowan-Jacob S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza C., Mohammed A., Neuberg D., Wright R.D., Gilliland D.G., and Griffin J.D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7 (2005) 129-141
14. Quintas-Cardama A., Kantarjian H., and Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug. Discov. 6 (2007) 834-848
15. Tokarski J.S., Newitt J.A., Chang C.Y., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y., Borzillerri R., Lombardo L.J., Xie D., Zhang Y., and Klei H.E. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66 (2006) 5790-5797
16. Vajpai N., Strauss A., Fendrich G., Cowan-Jacob S.W., Manley P.W., Grzesiek S., and Jahnke W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J. Biol. Chem. 283 (2008) 18292-18302
17. Francisco A.J., Ding Q., Taebo S., Anastasia V., Christine S., Yi L., Zhang G., Hur W., Ding S., Paul P.W., Mestan J., Fabbro D., and Gray N.S. Allosteric inhibitors of Bcr-Abl-dependent cell proliferation. Nat. Chem. Biol. 2 (2006) 95-102
18. J. Zhang, F.J. Adrian, W. Jahnke, S.W. Cowan-Jacob, A.G. Li, R.E. Iacob, T. Sim, J. Powers, C. Dierks, F. Sun, G.R. Guo, Q. Ding, B. Okram, Y. Choi, A. Wojciechowski, X. Deng, G. Liu, G. Fendrich, A. Strauss, N. Vajpai, S. Grzesiek, T. Tuntland, Y. Liu, B. Bursulaya, M. Azam, P.W. Manley, J.R. Engen, G.Q. Daley, M. Warmuth, N.S. Gray, Targeting wild-type and T315I Bcr-Abl by combining allosteric with ATP-site inhibitors, Nat. Chem. Biol. in press.
19. Seeliger M.A., Young M., Henderson M.N., Pellicena P., King D.S., Falick A.M., and Kuriyan J. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 14 (2005) 3135-3139
20. Wang W., Marimuthu A., Tsai J., Kumar A., Krupka H.I., Zhang C., Powell B., Suzuki Y., Nguyen H., Tabrizizad M., Luu C., and West B.L. Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl. Acad. Sci. 103 (2006) 3563-3568
21. Cowan-Jacob S.W., Fendrich G., Manley P.W., Jahnke W., Fabbro D., Liebetanz J., and Meyer T. c-Src crystal structure provides insights into c-Src activation. Structure 13 (2005) 861-871
22. Manley P.W., Cowan-Jacob S.W., and Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta 1754 (2005) 3-13
23. Hantschel O., Nagar B., Guettler S., Kretzschmar S., Dorey K., Kuriyan J., and Superti-Furga G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112 (2003) 845-857
24. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., and Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
25. Xu W., Harrison S.C., and Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385 (1997) 595-562
26. Harrison S.C. Variation on a Src-like theme. Cell 112 (2003) 737-740
27. Resh M.D. Myristylation and palmitylation of Src family members: the fats of the matter. Cell 76 (1994) 411-413
28. Choi Y., Seeliger M., Panjarian S.B., Kim H., Deng X., Sim T., Couch B., Koleske A.J., Smithgall T.E., and Gray N.S. N-myristoylated c-ABL tyrosine kinase localizes to the endoplasmatic reticulum upon binding to an allosteric inhibitor. J. Biol. Chem. 284 (2009) 29005-29014
29. Fabbro D., Buchdunger E., Wood J., Mestan J., Hofmann F., Ferrari S., Mett H., O'Reilly T., and Meyer T. Inhibitors of protein kinases: CGP 41251 a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. 82 (1999) 293-301
30. Azam M., Latek R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-840
31. Von Bubnoff N., Veach D.R., Van der Kuip H., Aulitzky W.E., Saenger J., Seipel P., Bornmann W.G., Peschel C., Clarkson B., and Duyster J. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105 (2005) 1652-1659
32. Wales T.E., and Engen J.R. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25 (2006) 158-170
33. Padmanabhan S., Ravella S., Curiel T., and Giles F. Current status of therapy for chronic myeloid leukemia: a review of drug development. Future Oncol. 4 (2008) 359-377
34. Haacke A., Fendrich G., Ramage P., and Geiser M. Chaperone over-expression in Escherichia coli: apparent increased yields of soluble recombinant protein kinases are due mainly to soluble aggregates. Protein Expr. Purif. 64 (2009) 185-193
35. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., and Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008) 127-132
36. Tokarski J.S., Newitt J.A., Chang C.Y.J., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y.F., Borzillerri R., Lombardo L.J., Xie D., Zhang Y., and Klei H.E. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66 (2006) 5790-5797
37. O'Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang F., Adrian L.T., Zhou T., Huang W.-S., Xu Q., Metcalf III C.A., Tyner J.W., Loriaux M.M., Corbin A.S., Wardwell S., Ning Y., Keats J.A., Wang Y., Sundaramoorthi R., Thomas M., Zhou D., Snodgrass J., Commodore L., Sawyer T.K., Dalgarno D.C., Deininger M.W.N., Druker B.J., and Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16 (2009) 401-412
38. Cortes J., Talpaz M., Deininger M., Shah N., Flinn I.W., Mauro M.J., O'Hare T., Spinos N., Hu S., Berk L., Narasimhan N., Rivera V.M., Clackson T., Haluska F., and Kantarjian H.M. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations (2009), ASH
39. Chou T.-C., and Talalay P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252 (1977) 6438-6442
40. Chou T.-C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou T.-C., and Rideout D.C. (Eds). Synergism and Antagonism in Chemotherapy (1991), Academic Press, San Diego, Calif. 61-102
41. Cowan-Jacob S.W., Moebitz H., and Fabbro D. Structural biology contributions to tyrosine kinase drug discovery. Curr. Opin. Cell Biol. 21 (2009) 280-28
42. Kornev A.P., Haste N.M., Taylor S.S., and Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. USA 103 (2006) 17783-17788
43. Azam M., Seeliger M.A., Gray N.S., Kuriyan J., and Daley G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15 (2008) 1109-1118
44. Cowan-Jacob S.W., Gabriele F., Floersheimer A., Furet P., Liebetanz J., Rummel G., Rheinberger P., Centeleghe M., Fabbro D., and Manley P.W. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr., D Biol. Crystallogr. 63 (2007) 80-93
45. Cowan-Jacob S., Guez V., Fabbro D., Fendrich G., Furet P., Liebetanz J., Mestan J., and Manley P.W. Bcr-Abl kinase mutations and drug resistance to imatinib (STI571). Mini Rev. Med. Chem. 4 (2004) 285-300
46. Nagar B., Hantschel O., Seeliger M., Davies J.M., Weis W.I., Superti-Furga G., and Kuryan J. Oragnization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol. Cell 21 (2006) 787-792
47. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., and Kuryan J. Structural basis for the autoinhbition of cAbl. Cell 112 (2003) 85-93